Klingenstein Fields & Co. LP decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,102 shares of the medical research company's stock after selling 2,046 shares during the quarter. Thermo Fisher Scientific comprises 1.9% of Klingenstein Fields & Co. LP's holdings, making the stock its 12th largest holding. Klingenstein Fields & Co. LP's holdings in Thermo Fisher Scientific were worth $42,517,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Coppell Advisory Solutions LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $33,000. Live Oak Investment Partners purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $36,000. Tyler Stone Wealth Management purchased a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $37,000. Raleigh Capital Management Inc. boosted its position in shares of Thermo Fisher Scientific by 49.1% during the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company's stock valued at $41,000 after buying an additional 27 shares during the last quarter. Finally, Cedar Mountain Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 107.0% during the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company's stock valued at $47,000 after buying an additional 46 shares during the last quarter. Institutional investors own 89.23% of the company's stock.
Thermo Fisher Scientific Stock Performance
Shares of NYSE:TMO traded up $3.26 during midday trading on Friday, reaching $544.78. 1,738,509 shares of the company traded hands, compared to its average volume of 1,199,852. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The firm has a market capitalization of $207.95 billion, a price-to-earnings ratio of 35.26, a price-to-earnings-growth ratio of 2.29 and a beta of 0.80. The firm's fifty day moving average price is $571.27 and its two-hundred day moving average price is $527.83.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same period in the previous year, the company posted $5.40 EPS. The firm's revenue for the quarter was down 4.9% compared to the same quarter last year. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current year.
Thermo Fisher Scientific Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific's dividend payout ratio is currently 10.10%.
Insiders Place Their Bets
In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the company's stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Debora L. Spar sold 164 shares of the company's stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the company's stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares of the company's stock, valued at $7,250,362. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock worth $28,513,384 in the last ninety days. 0.32% of the stock is currently owned by insiders.
Analyst Ratings Changes
Several research analysts recently issued reports on the company. Raymond James lifted their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an "outperform" rating in a research report on Thursday, February 1st. Barclays cut Thermo Fisher Scientific from an "overweight" rating to an "equal weight" rating and boosted their price objective for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. Royal Bank of Canada boosted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an "outperform" rating in a research report on Thursday, February 1st. Sanford C. Bernstein reissued a "market perform" rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Finally, HSBC boosted their price objective on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a "buy" rating in a research report on Wednesday. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average target price of $604.69.
Read Our Latest Research Report on TMO
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
